Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial

Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial

What insights can experts and survivors share about addiction? This conversation on *Addiction Medicine: Beyond the Abstract* zooms in on methamphetamine use disorder and how science is trying to catch up with a condition that still has no FDA‑approved medications. Journal host Zach talks with Dr Manish Jha, an associate professor of psychiatry at UT Southwestern, about his secondary analysis of the large ADAPT‑2 trial.

The study compared a combination of extended‑release injectable naltrexone and oral bupropion with placebo for methamphetamine use disorder, focusing on how craving and impulsivity relate to later meth use. Dr Jha explains how the team used frequent urine drug screens alongside simple self‑rated measures of craving and impulsivity.

He notes that, “the association between lower craving and higher likelihood of transitioning to a negative urine sample became stronger with time in the active combination,” while this link faded in the placebo group. That pattern hints that reducing craving might be a meaningful part of how the medication combination helps people cut down their use.

The discussion also touches on how naltrexone–bupropion may influence mood and impulsivity, why FDA guidance is shifting away from strict abstinence‑only outcomes, and how future treatments might directly target brain circuits involved in craving using tools like TMS, direct current stimulation, or focused ultrasound. Towards the end, Dr Jha turns to practical advice for clinicians and trainees.

He wishes his younger self had “focused more on measurement‑based care in the setting of addiction,” tracking not just urine tests but also craving, impulsivity and depression to see whether treatment is truly moving in the right direction. The episode closes with encouragement to use large public trial datasets to ask fresh research questions.

If you’re curious about how careful measurement can sharpen both research and clinical care in stimulant use disorders, this one’s worth your time—what changes might you bring into your own practice or study after hearing it?